NCT02334553

Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma

Phase IIa, Placebo-controlled, Randomized, Double-blind, Crossover Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 (8%) Administered by Nebulization in Subjects With Mild Atopic Asthma.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: SolAeroMed Inc. · Industry
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the safety and tolerability of a single dose of S-1226 (8%) in subjects with mild atopic asthma.

Detailed description

Phase IIa, placebo-controlled, randomized, double-blind, crossover single dose study to evaluate the safety, tolerability and efficacy of S-1226 (8%) administered by nebulization in subjects with mild atopic asthma

Conditions

• Asthma

Interventions

Type	Name	Description
DRUG	S1226(8%)	The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
DRUG	Placebo	Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response

Timeline

• Start date: 2015-02-06
• Primary completion: 2015-11-25
• Completion: 2015-11-25
• First posted: 2015-01-08
• Last updated: 2019-02-18

Locations

1 site across 1 country: Canada